Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial

Trial StartGRWD0715Positive

AI Analysis

Summary

Greywolf Therapeutics has dosed the first participants with GRWD0715, a novel first-in-class oral ERAP1 inhibitor, in an axSpA trial with clean single ascending dose safety data and a US patent grant.

Clinical Trial Data

Phase

Phase_1

Outcome Details

First-in-class oral ERAP1 inhibitor dosed in first axSpA participants; clean SAD safety data reported

Importance:6/10

Sentiment:

0.70

ERAP1_inhibitorfirst-in-classaxSpAoral_formulationsafety_datapatent_grant

Related Companies

$INTI $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 8, 2026 6:00 AM

Read Original